Betablockers: old concept in a modern approach

Area of Science:

• Cardiology
• Pharmacology
• Metabolic Medicine

Background:

• Hypertension and left ventricular hypertrophy are significant cardiovascular risk factors.
• Atherosclerosis progression is a major cause of cardiovascular morbidity.
• Beta-blockers are a cornerstone in managing cardiovascular diseases, but their metabolic effects can vary.

Purpose of the Study:

• To summarize the multifaceted effects of carvedilol.
• To highlight carvedilol's unique properties compared to traditional beta-blockers.
• To underscore carvedilol's potential benefits in cardiovascular and metabolic health.

Main Methods:

• Review of existing clinical studies and pharmacological data on carvedilol.
• Analysis of carvedilol's impact on blood pressure, cardiac structure, and metabolic parameters.
• Evaluation of carvedilol's effects on endothelial function, oxidative stress, and microalbuminuria.

Main Results:

• Carvedilol demonstrates effective blood pressure reduction and a decrease in left ventricular mass.
• The drug exhibits a favorable metabolic profile, including improved insulin sensitivity.
• Carvedilol positively influences the atherosclerotic process through enhanced endothelial function and antioxidant properties, also reducing microalbuminuria.

Conclusions:

• Carvedilol offers significant cardiovascular benefits beyond simple blood pressure lowering.
• Its distinct pharmacological profile suggests advantages over conventional beta-blocking agents.
• Ongoing research is exploring novel therapeutic applications of carvedilol's unique properties.